53. Sjogren syndrome Clinical trials / Disease details


Clinical trials : 305 Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2022-001484-27-NL
(EUCTR)
24/01/202329/10/2022Basta 2B cell Activation in Sjögren's Syndrome, Cutaneous Lupus Erythematodus and Systemic Sclerosis TissuesAnalysis 2 - Basta 2 Systemic Sclerosis Sjögren's SyndromeCutaneous Lupus Erythematodus;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Name: [89Zr]Zr-Df-crefmirlimab berdoxam
Product Code: IND 127861
INN or Proposed INN: [89Zr]Zr-Df-crefmirlimab berdoxam
Other descriptive name: Minibody against CD8 conjugated to desferrioxamine labeled with zirconium Zr 89
radboudumcNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Phase 2Netherlands